Valuation: Arrowhead Pharmaceuticals, Inc.

Market Cap 9.72B 8.47B 7.98B 7.27B 13.62B 931B 13.64B 95.56B 36.83B 474B 36.5B 35.69B 1,530B P/E 2026 *
-18.9x
P/E 2027 * -14.9x
Enterprise Value 8.88B 7.75B 7.3B 6.64B 12.46B 851B 12.47B 87.38B 33.68B 434B 33.37B 32.63B 1,399B EV / Sales 2026 *
19.3x
EV / Sales 2027 * 26.6x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -
09-16 Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 28th Annual Global Investment Conference, Sep-16-2026 09:00 AM
09-15 Arrowhead Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM
09-15 Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for Aro-Dimer-Pa Phase 1/2A Clinical Trial CI
09-10 Arrowhead Pharmaceuticals, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
09-08 Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target MT
08-31 Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says MT
08-31 Arrowhead Pharmaceuticals, Inc. - Special Call
08-31 Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia MT
08-30 Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 And SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events In Patients With Severe Hypertriglyceridemia CI
08-24 Arrowhead Pharmaceuticals Presents New Clinical Data and Product Updates At European Society of Cardiology Congress CI
08-20 Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,012,680, According to a Recent SEC Filing MT
08-17 Arrowhead Pharmaceuticals' Redemplo Now Available in Germany for FCS Patients MT
08-17 Arrowhead Pharmaceuticals Lists REDEMPLO In Lauer-Taxe Database As Adjunct To Diet To Reduce Triglyceride Levels In Adult Patients With Familial Chylomicronaemia Syndrome In Germany CI
1 day+3.47%
1 week-14.73%
Current month-16.51%
1 month-21.03%
3 months-15.93%
6 months+22.12%
Current year+3.62%
1 week 64.5
Extreme 64.5
71.93
1 month 64.5
Extreme 64.5
90.21
Current year 54.02
Extreme 54.02
95.49
1 year 31.46
Extreme 31.455
95.49
3 years 9.57
Extreme 9.57
95.49
5 years 9.57
Extreme 9.57
95.49
10 years 1.2
Extreme 1.2
95.49
Manager TitleAgeSince
Chief Executive Officer 56 2007-11-30
Director of Finance/CFO - 2025-05-12
Chief Tech/Sci/R&D Officer - 2022-07-31
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 2010-08-18
Director/Board Member 66 2011-12-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 Sell

Director

-2,000 0.0014%
8/18/26 Sell

Director

-11,600 0.0082%
6/15/26 Free

Director

11,882 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
+3.47%-14.73%+124.14%+152.63% 9.72B
+4.98%+5.73%+54.45%+113.83% 74.33B
-0.46%+0.58%+36.85%+80.94% 62.26B
-0.66%+6.97%+31.36%+23.45% 27.72B
+0.83%-3.43%-16.41%+359.38% 26.42B
+2.02%-0.87%+1.85%-7.92% 24.62B
-0.69%+4.37%+23.60%-11.27% 20.72B
-2.54%-3.36%+149.64%+324.48% 15.01B
-1.95%+1.80%+42.69%+165.15% 14.18B
-5.32%-8.25%-10.53%+823.50% 13.48B
Average -0.03%-0.81%+43.76%+202.42% 28.85B
Weighted average by Cap. +0.96%+1.69%+38.92%+149.12%

Financials

2026 *2027 *
Net sales 461M 402M 379M 345M 647M 44.18B 647M 4.54B 1.75B 22.51B 1.73B 1.69B 72.63B 340M 296M 279M 254M 477M 32.57B 477M 3.34B 1.29B 16.59B 1.28B 1.25B 53.53B
Net income -518M -452M -426M -388M -727M -49.67B -728M -5.1B -1.97B -25.3B -1.95B -1.9B -81.65B -650M -566M -533M -486M -911M -62.23B -912M -6.39B -2.46B -31.7B -2.44B -2.39B -102B
Net Debt -832M -726M -684M -622M -1.17B -79.74B -1.17B -8.19B -3.16B -40.62B -3.13B -3.06B -131B -683M -595M -561M -511M -957M -65.41B -959M -6.71B -2.59B -33.32B -2.56B -2.51B -108B
Logo Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
711
Date Price Change Volume
26-09-21 US$68.79 +3.47% 2,347,934
26-09-18 US$66.48 -1.86% 4,016,379
26-09-17 US$67.74 +2.96% 3,210,259
26-09-16 US$65.79 -6.91% 5,112,414
26-09-15 US$70.67 -12.40% 4,371,136
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
68.79USD
Average target price
110.00USD
Spread / Average Target
+59.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARWR Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!